MIG
RGLS

McGuire Investment Group’s Regulus Therapeutics RGLS Stock Holding History

McGuire Investment Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,500
Closed -$4K – 128
2022
Q1 		$4K Hold
1,500
– – ﹤0.01% 127
2021
Q4 		$5K Hold
1,500
– – ﹤0.01% 121
2021
Q3 		$10K Sell
1,500
-900
-38% -$6.59K ﹤0.01% 118
2021
Q2 		$20K Hold
2,400
– – ﹤0.01% 116
2021
Q1 		$37K Hold
2,400
– – 0.01% 109
2020
Q4 		$32K Hold
2,400
– – 0.01% 96
2020
Q3 		$12K Buy
2,400
+400
+20% +$2.63K ﹤0.01% 95
2020
Q2 		$14K Buy
2,000
+100
+5% +$655 ﹤0.01% 86
2020
Q1 		$9K Buy
+1,900
New +$16.6K ﹤0.01% 82

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

McGuire Investment Group's RGLS Position: Q2 2022 in Review

McGuire Investment Group sold out of Regulus Therapeutics (RGLS) in Q2 2022, closing a stake of 1,500 shares — an estimated $4K sold.

McGuire Investment Group first reported a position in RGLS in Q1 2020 and held it in 9 quarters. The position peaked at $37K in Q1 2021. 27 funds tracked by Wall St. Rank hold RGLS as of Q2 2022.

  • McGuire Investment Group reported no remaining Regulus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • McGuire Investment Group sold 1,500 Regulus Therapeutics shares in Q2 2022, an estimated $4K.
  • McGuire Investment Group first reported a position in Regulus Therapeutics in Q1 2020 and held it in 9 quarters.
  • McGuire Investment Group's Regulus Therapeutics position peaked at $37K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2022.

Based on McGuire Investment Group's 13F filing for Q2 2022, filed 15 Jul 2022.